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known that the level of 25(OH)D3 in circu-
lation is about ∼1000-fold higher than that 
of calcitriol. Th erefore, under normal con-
ditions, it is conceivable that many renal 
and extrarenal cells are capable of generat-
ing calcitriol from circulating 25(OH)D3 
to maintain a high local concentration of 
calcitriol for VDR-mediated autocrine 
and/or paracrine functions (Figure 2). 
However, this hypothesis raises more 
questions. For example, how does one 
investigate the signifi cance of these VDR-
mediated autocrine/paracrine functions 
in the cardiovascular system? Are these 
functions impaired in CKD? If yes, at what 
glomerular fi ltration rate does this mecha-
nism become impaired? Answers to these 
questions may help us further understand 
the benefi ts of VDR modulator therapy in 
reducing the CVD risk in CKD.
CONCLUSION
In summary, the paper by Chen et al.9 
provides interesting data showing that 
the regulation of NPR-A may be one of 
the mechanisms by which VDR activation 
is associated with cardiovascular benefi t 
in CKD.
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IgA nephropathy: Immune 
mechanisms beyond IgA mesangial 
deposition
A Rifai1
IgA nephropathy is attributable to mesangial IgA immune complex 
deposition. The pathogenic potential of frequently colocalized IgG 
deposits may depend on polarized T-helper cytokines that modulate 
Fcγ receptors of infiltrating macrophages, leading to either activation or 
inhibition that determines glomerular injury.
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In the complex web of potential mecha-
nisms implicated in the pathogenesis of 
IgA nephropathy, IgA glomerular depos-
its remain the sine qua non phenotype of 
the disease. Despite almost four decades 
of clinical and experimental investiga-
tions, the immunologic processes that 
induce and perpetuate glomerular IgA 
deposition remain a clinical challenge to 
identify. A decade after Jacque Berger’s 
seminal report of “IgA glomerular deposits 
in renal disease,” an experimental animal 
model was developed demonstrating that 
polymeric IgA immune complexes lead to 
IgA glomerular deposits. Th is was followed 
by a cascade of clinical investigations that 
reported IgA immune complexes in the cir-
culation and renal tissues of patients with 
IgA nephropathy. Now it is well recognized, 
as described in a comprehensive clinical 
review,1 that “primary IgA nephropathy is 
an immune-complex–mediated glomeru-
lonephritis defi ned immunohistologically 
by the presence of glomerular IgA deposits 
accompanied by a variety of histopatho-
logic lesions.” From this characterization it 
is implicit that not all IgA immune deposits 
possess equivalent pathogenic potential, as 
the glomerular landscape usually repre-
sents a wide spectrum that varies from 
minimal or no lesion to severe sclerosis. 
Th us, the enigma of glomerular IgA depo-
sition is wrapped in the mystery of absent 
correlation between the intensity of the 
IgA deposits and the extent of glomerular 
injury. Th e experimental fi ndings of Suzuki 
et al.2 (this issue) shed new investigative 
light to unwrap this mystery.
Over the years, several valuable experi-
mental models of IgA nephropathy have 
been developed that have provided 
insightful clues to the pathogenesis of 
the disease. Collectively, the experimen-
tal immunologic and histopathologic 
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findings in these models recapitulate 
the clinical condition. Among these 
models, the ddY model with spon-
taneous glomerular IgA deposition, 
described initially by Imai et al.,3 has 
been extensively investigated in Japan, 
in particular by the prolifi c laboratory of 
Yasuhiko Tomino. In this non-inbred 
strain of mice, IgA deposits occur at 
16 weeks of age. Onset of glomerular 
injury, however, is variable; it is promi-
nent at 20 weeks in some mice, is delayed 
to 40 weeks in some, and remains 
quiescent in others. On the basis of 
unparalleled large-scale performance and 
evaluation of open renal biopsy from 361 
mice, Suzuki et al.2 were able to sort the 
ddY mice into three groups: early onset, 
delayed onset, and quiescent. A central 
role of the bone marrow cells (BMCs) 
in development of IgA nephropathy was 
confirmed by transplantation among 
the groups. BMCs transplantation from 
quiescent (Q) donor to early-onset (EO) 
recipient markedly blunted the devel-
opment of injury in the EO group. In 
contrast, BMCs transplantation from an 
EO donor induced glomerular injury in 
Q recipients and aggravated the glomer-
ular lesion in EO recipients. Concur-
rent with the progression of glomerular 
lesion, there was a striking alteration 
in the glomerular deposits’ composi-
tion, whereby IgG2a colocalized with an 
intensity equal to that of IgA. Th e sig-
nifi cant correlation between the circulat-
ing level of serum IgA/IgG2a complexes 
and the glomerular injury score of the 
EO group is suggestive of causality. Th is 
prompted further investigation that com-
pared intracellular content and in vitro 
production of interferon-γ (IFN-γ) and 
interleukin-4 by mitogen-stimulated 
spleen T lymphocytes. Enhanced IFN-γ 
production in the EO group suggested 
T-helper 1 (Th 1)-polarized activity that 
contributed to the evolution of IgG2a 
immune deposits.
Knowledge about the role of T cell-
mediated immunity in general, and 
Th1/Th2 polarization in particular, 
in initiation and progression of clini-
cal IgA nephropathy is in short supply 
and is not well understood. Clinical 
reports of enhancement in both circu-
lating Th 1 and Th 2 T-lymphocyte sub-
sets, and of Th2 predominance at the 
single-cell level of analysis in patients 
with IgA nephropathy,4 need to be rec-
onciled with the postulate of Suzuki et 
al.2 More recently, Chao et al.,5 using a 
B cell-defi cient model of experimental 
IgA nephropathy, demonstrated that the 
antigen and cognate IgA immune com-
plexes activate T cells that indirectly, 
without infi ltrating the glomerulus, con-
tribute to injury. Th e requirement for T 
cells was evident by the failure of such 
immune deposits to induce glomerular 
injury in the same strain of mice with 
combined B- and T-cell defi ciency. It is of 
note that the attempt by Suzuki et al.2 to 
passively transfer T cells and serum from 
EO mice failed to induce IgA nephropa-
thy in recipient nude mice. Th is suggests 
that the stem cell in bone marrow is a 
prerequisite for the development of the 
disease. Most relevant to the observation 
of Th 1 polarization in the ddY model, the 
data of Suzuki et al.2 are highly consist-
ent with the previous report of Nogaki 
et al.,6 which showed increased IFN-γ 
Figure 1 | Postulated immunopathogenic mechanisms associated with IgA nephropathy 
in the ddY model. The simplified scheme illustrates how the pathogenic potential of an IgA 
immune complex (IgA-IC) glomerular immune deposit is influenced by the colocalized subclass 
IgA interaction with Fcγ receptors (FcγRs) on infiltrating macrophages that affects the magnitude 
of their activation and consequently the extent of glomerular injury. In this model, stem cells 
in the bone serve as a reservoir of autoimmune B cells that home to the mucosa of the gut-
associated lymphoreticular tissue (GALT) to generate polymeric IgA. T-helper 1 (Th1) polarization 
in the GALT will lead to B-cell immunoglobulin class switching favoring IgG2a that reacts with the 
antigenic component of the IgA-IC, generating a detrimental complex composite of IgA-IC-IgG2a. 
Conversely, a Th2 bias leads to production of IgG1 reactive with IgA-IC that generates complex 
composite of IgA-IC-IgG1 with low nephritogenic potential.  Circulating interferon-γ (IFN-γ) and 
interleukin-4 (IL-4) produced, respectively, by Th1 and Th2 in the GALT modulate glomerular injury 
by affecting FcγR expression on macrophage infiltrates and consequently the magnitude of their 
activation by the IgA-IC–IgG deposit. ITAM, immunoreceptor tyrosine-based activation motif; ITIM, 
immunoreceptor tyrosine-based inhibition motif.
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and decreased interleukin-4 produc-
tion by mitogen-stimulated CD4+ cells 
from ddY mice producing high IgA. 
Of great interest also is that, in the fi rst 
description of the ddY model, Imai et al.3 
reported a steep rise of IgG2a at 40 weeks 
that coincided with defi nitive mesangial 
proliferation. Nonetheless, the most sig-
nifi cant aspect of the fi ndings of Suzuki 
et al.2 is the detection of circulating IgA 
immune complexes containing IgG2a, 
whose level correlated with the score of 
glomerular injury. Although the source 
and composition of such complexes are 
unknown, their nephritogenic potential 
is ascertained.
What are the source and antigen com-
position of IgA/IgG2a immune com-
plexes in ddY mice, and how do they 
precipitate in glomerular injury? Suzuki 
et al.2 extensively discuss their fi ndings in 
terms of Th 1 polarization; this need not 
be reiterated here. A diff erent perspective 
on their results, however, compels me to 
postulate that glomerular injury emerges 
from the convergence of diff erent eff ec-
tors and mediators. It is well established 
that stem cells in the adult mouse bone 
marrow represent the cellular reservoir 
of B-1 cells that are selected by self-
antigens; this B-1 repertoire tends to be 
autoreactive and plays an important role 
in mucosal immunity. Th e decrement in 
albuminuria, observed by Suzuki et al.2 
in the irradiated EO recipients between 
weeks 1 and 5 aft er transplantation of 
BMCs from similar EO donors, suggests 
this latency period might be required by 
the transplanted autoimmune B cells for 
repopulating the lymphoid organs before 
they differentiate into autoantibody-
producing cells. Earlier insightful stud-
ies by Kawaguchi7 examined and com-
pared Peyer’s patches and spleen cells 
of ddY mice at 40 weeks and concluded 
that gut-associated lymphoreticular tis-
sue, not the spleen, plays an important 
role in the pathogenesis of the high IgA 
response and glomerular IgA deposition 
observed in this strain. Furthermore, 
Wakui et al.8 reported that ddY mice 
develop mainly IgG-class and partly 
IgA-class anti-histone autoantibody 
aft er 40 weeks of age, and that histone–
anti-histone complexes may contrib-
ute to the development of murine 
glomerulopathy. Like the B cells, 
autoimmune T cells in gut-associated 
lymphoreticular tissue may contribute 
to injury. In support of this conjecture is 
the elegant experimental model reported 
by Wang et al.,9 who demonstrated 
that T cell-mediated mucosal immu-
nity concurrent with the appearance of 
anti-DNA antibodies leads to severe I
gA nephropathy.
IgA immune complexes (IgA-IC) con-
taining IgG antibody glomerular depos-
its are a well-recognized feature of IgA 
nephropathy. Th eir pathogenic signifi -
cance, however, has not been elucidated. 
Th is may be due to divergent activities of 
IgGs that can now be explained through 
selective engagement of their isotype-
constant Fc region with specifi c cellular 
receptors (FcγRs). Structurally, four dif-
ferent classes of FcγRs have been iden-
tifi ed with diff erent affi  nities that vary 
from high (FcγRI) to low (FcγRII and 
FcγRIII), with the most recently discov-
ered, FcγRIV, having selective and inter-
mediate affi  nity for mouse IgG2a and 
IgG2b.10 Th e majority of these receptors 
(FcγRI, FcγRIII, FcγRIV) are classifi ed as 
activating, because they transmit intra-
cellular signaling via immunoreceptor 
tyrosine-based activation motif (ITAM), 
whereas FcγRIIB is inhibitory, as it 
transmits signal via immunoreceptor 
tyrosine-based inhibition motif (ITIM). 
As illustrated in Figure 1, a simplifi ed 
model postulates that glomerular injury 
is dependent on the activation status of 
infi ltrating macrophages. Th e composite 
IgA-IC–IgG2a isotype interaction with 
the paired expression of activating and 
inhibitory receptors causes a high acti-
vation-to-inhibition ratio, triggering 
generation of mediators that produce 
injury. By comparison, the compos-
ite IgA-IC–IgG1 isotype, with higher 
affi  nity for the inhibitory FcγRIIB and 
a lack of interaction with the activating 
FcγRI and FcγRIV receptors, produces 
a low activation-to-inhibition ratio, 
keeping the macrophage quiescent with 
minimal or no injury. It is of note that 
the proinfl ammatory extrarenal IFN-
γ potentiates IgA-IC–IgG2a deposits 
by upregulating activating FcγRs and 
blocking expression of the inhibitory 
FcγRIIB. Conversely, interleukin-4 
upregulates the inhibitory FcγRIIB on 
macrophages, thereby dampening fur-
ther the pathogenic potential of IgA-IC–
IgG1 complexes. As is indicated above, 
this minimalist framework model is far 
from being comprehensive. It does not 
account for the important roles of the 
antigen, complement system, genetic 
background, and a host of unknown 
epistatic modifi ers involved in disease 
susceptibility and severity.
Th e promising experimental fi ndings 
of Suzuki et al.2 usher in an exciting era 
in IgA nephropathy research: the era of 
correlating the nature of the immune 
deposits with glomerular progression 
to injury. Th e new investigations also 
encourage us to continue to build on 
the experimental models as a roadmap 
for which clinical studies to pursue. Th e 
intensive experimental work is bear-
ing fruit and shows a solid potential to 
bridge the gaps in our knowledge of IgA 
nephropathy.
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